Immunology and the Elusive AIDS Vaccine

Overview

Journal Nature

Specialty Science

Date 2010 Mar 12

PMID 20220841

Citations 76

Authors

Herbert W Virgin

Bruce D Walker

Affiliations

Soon will be listed here.

Abstract

Developing a human immunodeficiency virus (HIV) vaccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but many question whether this goal is achievable. Natural immunity is not protective, and despite immunogenicity of HIV vaccine candidates, human trials have exclusively yielded disappointing results. Nevertheless, there is an indication that success may be possible, but this will be dependent on understanding the antiviral immune response in unprecedented depth to identify and engineer the types of immunity required. Here we outline fundamental immunological questions that need to be answered to develop a protective HIV vaccine, and the immediate need to harness a much broader scientific community to achieve this goal.

Citing Articles

Chemoenzymatic Synthesis and Antibody Binding of HIV-1 V1/V2 Glycopeptide-Bacteriophage Q Conjugates as a Vaccine Candidate.

Zong G, Toonstra C, Yang Q, Zhang R, Wang L Int J Mol Sci. 2021; 22(22).

PMID: 34830420 PMC: 8617853. DOI: 10.3390/ijms222212538.

Persistent lentivirus infection induces early myeloid suppressor cells expansion to subvert protective memory CD8 T cell response.

Liu L, Lin Q, Peng J, Fang J, Tan Z, Tang H EBioMedicine. 2020; 60:103008.

PMID: 32979832 PMC: 7519271. DOI: 10.1016/j.ebiom.2020.103008.

Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors.

Alam M, Kuwata T, Tanaka K, Alam M, Takahama S, Shimura K Biochem Biophys Rep. 2019; 20:100687.

PMID: 31650039 PMC: 6804516. DOI: 10.1016/j.bbrep.2019.100687.

On the efficiency of HIV transmission: Insights through discrete time HIV models.

Showa S, Nyabadza F, Hove-Musekwa S PLoS One. 2019; 14(9):e0222574.

PMID: 31532803 PMC: 6750597. DOI: 10.1371/journal.pone.0222574.

High-level expression of the HIV entry inhibitor griffithsin from the plastid genome and retention of biological activity in dried tobacco leaves.

Hoelscher M, Tiller N, Teh A, Wu G, Ma J, Bock R Plant Mol Biol. 2018; 97(4-5):357-370.

PMID: 29948657 PMC: 6061503. DOI: 10.1007/s11103-018-0744-7.

References

Bushman F, Malani N, Fernandes J, DOrso I, Cagney G, Diamond T . Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 2009; 5(5):e1000437. PMC: 2682202. DOI: 10.1371/journal.ppat.1000437. View

Scheid J, Mouquet H, Feldhahn N, Seaman M, Velinzon K, Pietzsch J . Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458(7238):636-40. DOI: 10.1038/nature07930. View

Chen L, Kwon Y, Zhou T, Wu X, ODell S, Cavacini L . Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 2009; 326(5956):1123-7. PMC: 2862588. DOI: 10.1126/science.1175868. View

Salazar-Gonzalez J, Salazar M, Keele B, Learn G, Giorgi E, Li H . Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009; 206(6):1273-89. PMC: 2715054. DOI: 10.1084/jem.20090378. View

Goepfert P, Lumm W, Farmer P, Matthews P, Prendergast A, Carlson J . Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med. 2008; 205(5):1009-17. PMC: 2373834. DOI: 10.1084/jem.20072457. View

Nakanishi Y, Lu B, Gerard C, Iwasaki A . CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature. 2009; 462(7272):510-3. PMC: 2789415. DOI: 10.1038/nature08511. View

Cohen M, Hellmann N, Levy J, DeCock K, Lange J . The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest. 2008; 118(4):1244-54. PMC: 2276790. DOI: 10.1172/JCI34706. View

Miura T, Brockman M, Schneidewind A, Lobritz M, Pereyra F, Rathod A . HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol. 2009; 83(6):2743-55. PMC: 2648254. DOI: 10.1128/JVI.02265-08. View

Fowke K, Nagelkerke N, Kimani J, Simonsen J, Anzala A, Bwayo J . Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet. 1996; 348(9038):1347-51. DOI: 10.1016/S0140-6736(95)12269-2. View

10.

Fields B . AIDS: time to turn to basic science. Nature. 1994; 369(6476):95-6. DOI: 10.1038/369095a0. View

11.

Petrovas C, Casazza J, Brenchley J, Price D, Gostick E, Adams W . PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006; 203(10):2281-92. PMC: 2118095. DOI: 10.1084/jem.20061496. View

12.

Yi J, Du M, Zajac A . A vital role for interleukin-21 in the control of a chronic viral infection. Science. 2009; 324(5934):1572-6. PMC: 2736049. DOI: 10.1126/science.1175194. View

13.

Haase A . Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010; 464(7286):217-23. DOI: 10.1038/nature08757. View

14.

Lund J, Hsing L, Pham T, Rudensky A . Coordination of early protective immunity to viral infection by regulatory T cells. Science. 2008; 320(5880):1220-4. PMC: 2519146. DOI: 10.1126/science.1155209. View

15.

Sodora D, Allan J, Apetrei C, Brenchley J, Douek D, Else J . Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med. 2009; 15(8):861-5. PMC: 2782707. DOI: 10.1038/nm.2013. View

16.

Vignuzzi M, Stone J, Arnold J, Cameron C, Andino R . Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2005; 439(7074):344-8. PMC: 1569948. DOI: 10.1038/nature04388. View

17.

Fauci A, Johnston M, Dieffenbach C, Burton D, Hammer S, Hoxie J . HIV vaccine research: the way forward. Science. 2008; 321(5888):530-2. DOI: 10.1126/science.1161000. View

18.

Kaufmann D, Kavanagh D, Pereyra F, Zaunders J, Mackey E, Miura T . Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007; 8(11):1246-54. DOI: 10.1038/ni1515. View

19.

Klatt N, Villinger F, Bostik P, Gordon S, Pereira L, Engram J . Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J Clin Invest. 2008; 118(6):2039-49. PMC: 2391063. DOI: 10.1172/JCI33814. View

20.

Zhu J, Koelle D, Cao J, Vazquez J, Huang M, Hladik F . Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007; 204(3):595-603. PMC: 2137910. DOI: 10.1084/jem.20061792. View